Week one FLT-PET response predicts complete remission to R-CHOP and survival in DLBCL by Herrmann, Ken et al.
Oncotarget4050www.impactjournals.com/oncotarget
www.impactjournals.com/oncotarget/ Oncotarget, Vol. 5, No. 12
Week one FLT-PET response predicts complete remission to 
R-CHOP and survival in DLBCL
Ken Herrmann1,2,*, Andreas K. Buck1,2,*, Tibor Schuster3, Kathrin Abbrederis4, 
Christina Blümel2, Ivan Santi1, Martina Rudelius5,6, Hans-Jürgen Wester1, Christian 
Peschel4, Markus Schwaiger1, Tobias Dechow4,7 and Ulrich Keller4
1 Department of Nuclear Medicine, Technische Universität München, Munich, Germany 
2 Department of Nuclear Medicine, Universitätsklinikum Würzburg, Würzburg, Germany
3 Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Canada
4 III. Medical Department, Technische Universität München, Munich, Germany
5 Institute of Pathology, Technische Universität München, Munich, Germany
6 Institute of Pathology, Universitätsklinikum Würzburg, Würzburg, Germany
7 Oncology Ravensburg, Ravensburg, Germany
* These Authors contributed equally to this work
Correspondence to: Ulrich Keller, email: ulrich.keller@lrz.tum.de
Correspondence to: Ken Herrmann, email: Herrmann_K1@ukw.de
Keywords: Lymphoma; DLBCL; Positron emission tomography; [18F]Fluorodeoxythymidine; FLT-PET
Received: March 28, 2014 Accepted: May 17, 2014 Published: May 19, 2014
This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, 
distribution, and reproduction in any medium, provided the original author and source are credited. 
ABSTRACT
Despite improved survival in the Rituximab (R) era, a considerable number of 
patients with diffuse large B-cell lymphoma (DLBCL) ultimately die from the disease. 
Functional imaging using [18F]fluorodeoxyglucose-PET is suggested for assessment of 
residual viable tumor very early during treatment but is compromised by non-specific 
tracer retention in inflammatory lesions. The PET tracer [18F]fluorodeoxythymidine 
(FLT) as surrogate marker of tumor proliferation may overcome this limitation. We 
present results of a prospective clinical study testing FLT-PET as superior and early 
predictor of response to chemotherapy and outcome in DLBCL. 54 patients underwent 
FLT-PET prior to and one week after the start of R-CHOP chemotherapy. Repetitive 
FLT-PET imaging was readily implemented into the diagnostic work-up. Our data 
demonstrate that the reduction of FLT standard uptake valuemean (SUVmean) and SUVmax 
one week after chemotherapy was significantly higher in patients achieving complete 
response (CR, n=48; non-CR, n=6; p<0.006). Martingale-residual and Cox proportional 
hazard analyses showed a significant monotonous decrease of mortality risk with 
increasing change in SUV. Consistent with these results, early FLT-PET response 
showed relevant discriminative ability in predicting CR. In conclusion, very early FLT-
PET in the course of R-CHOP chemotherapy is feasible and enables identification of 
patients at risk for treatment failure.
INTRODUCTION
CHOP (cyclophosphamide, doxorubicine, 
vincristine and prednisone) or CHOP-like chemotherapy 
in combination with the chimeric monoclonal anti-CD20 
antibody rituximab (R) is the standard of care in diffuse 
large B-cell lymphoma (DLBCL). Despite improved 
overall response rates and progression free (PFS) as 
well as overall survival (OS) in the R era, a considerable 
fraction of patients does not achieve a durable remission 
after first line treatment and will ultimately die from the 
disease. Therefore, it remains crucial to identify these 
patients prior to or early in the course of treatment [1-3].
DLBCL is heterogeneous with respect to biology 
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and clinical course. The international prognostic index 
(IPI) allows estimation of the individual prognosis based 
on easily available parameters [4] and has remained useful 
for risk estimation in the rituximab era [5]. Important 
insights into the molecular biology of this entity have been 
gained with the introduction of DNA microarrays, which 
provide a genome-wide profile of mRNA expression 
levels in cancer samples. Gene expression profiling (GEP) 
studies support the view that DLBCL is a heterogeneous 
diagnostic category, as 3 molecular subtypes, termed 
germinal center B-cell (GCB) DLBCL, activated 
B-cell (ABC) DLBCL, and primary mediastinal B-cell 
lymphoma (PMBL), could be detected, which are often 
indistinguishable using conventional diagnostic tools. 
These diagnostic DLBCL categories have significantly 
different survival rates after standard treatment [6-9].
A different attempt to identify patients with higher 
risk of treatment failure is to perform functional PET 
imaging. However, while interim FDG-PET has proven 
useful to identify patients that have an excellent prognosis 
after standard treatment, this modality has heretofore 
failed to accurately identify patients who would benefit 
from alternative treatment strategies or who should be 
included into clinical trials due to dismal outcome with 
R-CHOP-like therapy [10-13]. An earlier identification 
of patients using an alternative radiotracer that allows 
response assessment immediately after initiation of 
chemotherapy may be beneficial. A promising candidate 
is the thymidine analog 3`-deoxy-3`-[18F]fluorothymidine 
(FLT), a PET tracer derived from the cytostatic drug 
azidovudine (AZT), that allows in vivo imaging of 
proliferating tissues and malignant tumors [14]. Recently, 
published studies demonstrated a significant correlation 
of tumor cell proliferation and FLT uptake in lymphoma 
and solid tumors [15-21]. Recent studies have also shown 
that FLT-PET allows non-invasive assessment of tumor 
grading, very early response assessment, and possibly 
survival [15, 19, 22-24] in experimental animal models 
and patients.
Predictive markers are desirable for guiding 
risk-adjusted treatment in lymphoma. The aim of this 
prospective study was to assess the suitability of FLT and 
in particular the decrement of FLT uptake one week after 
start of immuno-chemotherapy to predict response and 
clinical outcome in patients with DLBCL.
RESULTS
Response to therapy and survival
54 patients met the inclusion criteria and completed 
the full protocol. Staging was performed according to 
established standards using CT/PET-CT scans as the 
reference method. Results are shown in Table 1. End 
of therapy assessment was available in 52 patients and 
indicated CR in 46 patients, PR in 2 patients, and PD 
was found in 4 patients, respectively. Importantly, FDG-
positivity was found in 5 of the 32 patients with end of 
treatment FDG-PET, including 4 patients in the non-CR 
group. Two patients were lost to follow-up. Recurrence 
and death were reported in 6 (11%) and 7 (13%) patients 
respectively. The estimated 1-, 3- and 5-year recurrence 
free survival probabilities (95% confidence interval) 
were 0.94 (0.89 to >0.99), 0.90 (0.81 to 0.99) and 0.78 
(0.59 to >0.99). The respective estimated overall survival 
probabilities were 0.94 (0.89 to >0.99), 0.89 (0.80 to 0.99) 
and 0.76 (0.59 to 0.97) (Fig. 1).
FLT uptake reduction one week after 
chemotherapy
Mean uptake of FLT-1 in lymphoma manifestations 
(mean FLT-1 SUV) was 7.3 (range 1.0 – 18.2). 
Corresponding maximum FLT-1 uptake values ranged 
from 1.2 – 20.4, resulting in a mean of FLT-1 SUVmax 
of 9.3. Mean SUVmean decreased one week after start 
of treatment (FLT-2) to 1.8 (range 0.3 – 7.4) (Table 2), 
resulting in a mean decrease of 73.1% (range: 0.0% - 
95.8%) (Table 2). Corresponding SUVmax values of FLT-
2 PET were 2.4 (range: 0.4 – 9.6) calculating to a mean 
decrease of 73.6% (range: 10.8% - 96.1%) for change of 
SUVmax (Table 2,). Thus, FLT PET performed one week 
after standard treatment results in a substantial decrease in 
both mean and maximal tracer uptake.
Figure 1: Kaplan-Meier curve depicting estimated 
overall survival probabilities. Shaded area indicates the 
95% confidence interval for the survival function. Observation 
times of individuals without fatal event (censored cases) are 
marked with the symbol +. 
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FLT-2 SUVmean/max predict achieving a CR
Next, the FLT-2 data was analyzed for the predictive 
value of FLT-2 with regard to achieving a CR. Due to 
the low number of patients with PR or PD, FLT uptake 
parameters were compared for patients in CR (n=48) 
and patients in non-CR (n=6). FLT-2 uptake values one 
week after treatment initiation were significantly lower 
in patients achieving a CR compared to non-CR patients 
(mean SUVmean: P=0.006; mean SUVmax: P=0.005, Table 
3), the patient group that contained 4 patients with a 
positive FDG-PET at end of treatment. Thus, FLT uptake 
one week after treatment is predictive for achieving a CR.
We also calculated whether the decrement in 
either FLT SUV was predictive. The mean decrease of 
SUVmean and SUVmax was higher in patients achieving 
CR (mean SUVmean-decrease: 73.6%, median: 79.7% and 
mean SUVmax-decrease: 74.4%, median: 80.1%, Table 3) 
compared to non-CR patients (mean SUVmean-decrease: 
65.7%, median 70.5% and mean SUVmax-decrease: 
63.2%, median 65.5%, Table 3). ROC analyses resulted 
in areas under the curves of 0.622 (95%CI: 0.44-0.80) for 
SUVmean and 0.655 (95% CI: 0.48 – 0.83) for changes 
of SUVmax to predict complete response (Fig. 2). 
Corresponding optimal cut-offs calculated to a decrease 
of 79.0% SUVmean to predict a CR (positive predictive 
value: 92.6%) and, respectively, 82.0% SUVmax to 
predict a CR (positive predictive value: 95.7%)
Association of FLT uptake parameters and 
survival
Six of 54 patients either progressed or relapsed after 
achieving a response to initial treatment and 7 patients 
died during the observation period (Fig. 2). Of the 7 deaths 
4 were lymphoma-related (7.4%). Martingale-residual 
analysis was performed for all seven death events and 
revealed a significant correlation between survival and 
change of SUV (Fig. 3). The corresponding estimated 
hazard ratios per one-point increment of FLT-SUVmean and 
FLT-SUVmax were 0.65 (95% CI: 0.50 to 0.84, p=0.001) 
and 0.60 (95% CI: 0.44 to 0.83, p=0.002) respectively. 
Figure 2: Diagnostic accuracy regarding prediction of 
complete remission using SUV decrease. A, SUVmean 
decrease. B, SUVmax decrease. Sens: sensitivity; Spec: 
specificity; PV+: Positive predictive value; PV-: negative 
















































Table 1: Patient characteristics.
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DISCUSSION
The thymidine analogue FLT has been shown to 
reflect proliferation-dependent retention of nucleosides 
in malignant lymphoma, which can be assessed non-
invasively by PET [25]. Several studies testing interim 
FDG-PET after 2-4 cycles of therapy have heretofore 
failed to identify patients who would benefit from 
alternative treatment strategies or who should be included 
into clinical trials due to dismal outcome with R-CHOP-
like therapy [10-13]. Here we used very early interim 
FLT-PET performed one week after treatment initiation to 
test the hypothesis that, firstly, the drop in proliferation 
measured by FLT uptake/ retention and, secondly, the 
remaining FLT uptake (FLT-2 SUV) may allow predicting 
not only treatment response but also survival.
In concordance with the recent report of Lee and 
colleagues [24] our similarly designed study (FLT-PET 
day 7 after cycle 1 vs. before cycle 2) that included a 
comparable number of patient also points to early FLT-
PET assessment as a prognostic/ predictive factor with 
regard to response and survival. Assuming that very 
early FLT-PET assessment should reflect immediate 
treatment efficacy we deliberately chose this very short 
interval between treatment initiation and second FLT-PET 
imaging. Concluding from the comparison of these two 
studies however the very early assessment performed 
at day 7 might be too early and therefore inferior. It is 
possible that the use of immunotherapy may increase 
Figure 3: Martingale-residual analysis: decrease in A, SUVmean and B, SUVmax and the risk of death in patients achieving 
a complete remission (CR) or not (PR: partial response; PD: progressive disease). Solid lines depict smoothing functions with 95% 
confidence bands. Decreasing Martingale-residual values with higher decrease in SUVmean / SUVmax indicate a decline in risk of death 
with higher SUV decrement.
Table 2: FLT-1 and FLT-2 parameters. FLT-1: 
represents the FLT parameters before treatment. FLT-2: 
represents the FLT parameters one week after treatment 
initiation. ΔSUV: represents the change of SUV measured 
in FLT-1 to FLT-2 (ΔSUV=100 - [SUV FLT-1 – SUV 
FLT2] x 100).
Parameter Mean Median Minimum Maximum
SUVmean 
FLT-1 7.3 7.0 1.0 18.2
SUVmax FLT-
1 9.3 9.0 1.2 20.4
SUVmean 
FLT-2 1.8 1.2 0.3 7.4
SUVmax FLT-
2 2.4 1.5 0.4 9.6
ΔSUVmean 73.1 78.3 0.0 95.8
ΔSUVmax 73.6 77.7 10.8 96.1
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lesion inflammation. Since the mode of supposed action 
for rituximab involves, next to direct pro-apoptotic 
or complement-mediated effects [26] also antibody-
dependent cellular cytotoxicity via the Fc fragment 
of the antibody [27], the interval selected in our study 
could be too short to optimally assess treatment efficacy. 
Similarly, FDG measurement requires a minimum interval 
to immuno-chemotherapy due to a transient increase in 
stromal reaction that may result in overestimation of the 
fraction of viable cells [28]. The recommendations by 
the European Organization for Research and Treatment 
of Cancer consider a time interval of one to two weeks 
between completion of a chemotherapy cycle and FDG 
PET optimal to avoid transient flare at the disease sites 
[29]. Thus a certain delay may be more suitable for 
FLT-PET, too. On the other hand our study clearly 
demonstrates in a large cohort that the decrement in FLT 
uptake briefly after one therapy cycle is quite substantial. 
We define an optimal cut-off value for SUVmean (79%) 
and SUVmax (82%) decrease predictive for achieving a 
complete remission, an important prognostic factor in first 
line treatment of DLBCL [30].
Besides the above discussed limitations of our 
study regarding the very early time point of assessment, 
the moderate power to predict survival is however clearly 
limited by the bias towards a patient cohort not under 
immediate treatment pressure. Although synthesis is 
highly standardized, FLT remains an experimental PET 
tracer and was therefore only available once a week at 
our institution. This limitation did not allow us to include 
more patients with adverse prognostic factors, and reduced 
performance status due to lymphoma activity is a very 
important adverse prognostic factor [4]. Including patients 
selected for adverse prognostic factors determined for 
example by IPI score (4, 5), molecular assessment (31-33) 
or also by advanced not yet broadly available techniques 
(34-37) should allow to define a high risk population 
more exactly than one single approach alone. Such a high 
risk patient selection would also come by assessing the 
suitability of FLT for early prediction of treatment failure 
in a refractory/relapsed patient cohort [38].
To our knowledge we present results of one of 
only two prospective studies investigating the predictive 
value of very early interim FLT-PET regarding response 
to treatment and survival in aggressive B-NHL. Despite 
the favourable prognosis and outcome of patients in our 
series, a significant role of FLT-PET for early survival 
prediction could be demonstrated. However, although 
Table 3: FLT uptake values depending on response.
Figure 4: PET imaging and treatment schedule
Parameter Mean Median Minimum Maximum P-Value
FLT-1 SUVmean non-CR-group 9.3 8.8 6.2 13.7
0.073
FLT-1 SUVmean CR group 7.2 7.0 1.0 18.2
FLT-1 SUVmax non-CR-group 10.9 10.6 7.0 16.4
0.265
FLT-1 SUVmax CR group 9.2 8.8 1.2 20.4
FLT-2 SUVmean non-CR-group 3.4 2.2 1.9 7.4
0.006
FLT-2 SUVmean CR group 1.7 1.1 0.3 7.4
FLT-2 SUVmax non-CR-group 4.2 2.8 2.4 8.9
0.005
FLT-2 SUVmax CR group 2.2 1.4 0.4 9.6
Decrease SUVmean  non-CR-group 65.7 70.5 46.0 78.1
0.089
Decrease SUVmean CR group 73.6 79.7 0.0 95.8
Decrease SUVmax  non-CR-group 63.2 65.5 45.7 78.0
0.064
Decrease SUVmax CR group 74.4 80.1 10.8 96.1
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the study results suggest potential usefulness of FLT-PET 
for response prediction (upper confidence limits of the 
estimated discrimination indices >0.8), further studies 
need to be conducted to establish optimal thresholds 
and to define more precisely the associated predictive 
performance. Several adjustments with regard to timing 
and patient selection in upcoming trials investigating FLT 
or other novel PET tracers will be required.
METHODS
Patients
54 patients with biopsy proven aggressive B-cell 
Non-Hodgkin lymphoma (B-NHL) were included in 
this prospective study and completed the full FLT-PET 
imaging protocol (26 men, 28 women, mean age: 58 ± 15 
years). All patients were scheduled to undergo systemic 
chemotherapy with R-CHOP-like treatment. Detailed 
patient characteristics and risk factors are shown in Table 
1. 
All 54 patients underwent a pre-therapeutic FLT-
PET scan (FLT-1) as well as second scan (FLT-2) one week 
after start of treatment (Fig. 4). Exclusion criteria included 
previous or concurrent malignancies, preceding chemo- or 
radiotherapy, and patients younger than 18 years. Details 
of the study were explained by a physician and written 
informed consent was obtained from all patients. The 
study protocol was approved by the responsible ethics 
committee of the Technische Universität München.
Study design
Baseline FLT-PET examination (FLT-1) was 
performed within 1 week before therapy, together with 
standard staging modalities (clinical examination, CT). As 
FDG-PET is not routinely reimbursed in Germany, it was 
available only for initial staging in a subgroup of patients 
(n=32). FLT-PET imaging was repeated in all 54 patients 
around one week after the start of the first course of 
R-CHOP treatment (FLT-2) (range, day 5 to day 8, mean 
6.3 days). An end of therapy FDG-PET as recommended 
by the revised response criteria published in 2007 was 
performed in 32 of the patients.
Patients received R-CHOP therapy in standard dose 
(rituximab 375 mg/m2, cyclophosphamide 750 mg/m2 day 
1, doxorubicin 50 mg/m2 day 1, vincristine 1.4 mg/m2 day 
1 and prednisone 100 mg day 1-5) every 2 or 3 weeks 
with dose modification or delays according to common 
standards. 3 patients received additional etoposide 100mg/
m2 day 1-3 (R-CHOEP) and in one patient liposomal 
doxorubicin was used with 30 mg/m² per day.
Histopathological classification
Histology of lymphomas was classified according 
to the updated WHO classification system [39]. In all 54 
patients histopathology revealed aggressive B-NHL (Table 
1), including 52 patients with DLBCL and 2 patients with 
follicular lymphoma (FL) grade 3b.
PET Imaging
3’-deoxy-3’-[18F]fluorothymidine was synthesized 
as previously described [40]. Imaging was performed on 
a whole-body high resolution PET scanner (ECAT HR+; 
Siemens/CTI; Knoxville, TN). This device simultaneously 
acquires 47 contiguous slices with a slice thickness of 3.4 
mm. The in-plane image resolution of transaxial images 
was approximately 8 mm full width at half maximum 
(FWHM), with an axial resolution of approximately 5 mm 
FWHM.
Static emission images were acquired 45 minutes 
after injection of approximately 300 MBq FLT (range: 270 
– 340 MBq). Emission data were corrected for random 
coincidences, dead time and attenuation and reconstructed 
by filtered backprojection (Hanning filter with cut-off 
frequency 0.4 cycle per bin). The matrix size was 128 x 
128 pixels with a pixel size of 4.0 x 4.0 mm. The image 
pixel counts were calibrated to activity concentrations 
(Becquerel/milliliter) and decay corrected using the time 
of tracer injection as reference. 
PET Data Analysis
All PET scans were evaluated by two observers 
(board-certified nuclear medicine specialists) blinded to 
the clinical data and the results of other imaging studies. 
Circular regions of interest (ROIs) with a diameter of 1.5 
cm were placed in the area with the highest tumor activity, 
as previously published [41]. Mean lesion diameter and 
range of initial tumor size were 4.6 cm (median: 4.0, 
range: 2.0-17.5). Mean standardized uptake values (SUV) 
were calculated from each ROI using the formula: SUV 
= measured activity concentration (Bq/g) x body weight 
(g)/injected activity (Bq). For further analyses, mean 
values from both observers were used. Side-by-side 
analysis has been performed to ensure SUV-calculation in 
identical ROIs at various time points. This algorithm has 
been demonstrated to be a valuable tool for assessment of 
treatment response [41, 42]. 
For definition of ROIs and data analysis, computer 
programs were developed in the Interactive Data 
Language (IDL; Research Systems, Inc., Boulder, Co) 
using the Clinical Application Programming Package 
(CAPP; Siemens/CTI, Inc.) [43]. 
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Clinical Evaluation and Follow-up
CT was performed as part of the routine clinical 
management in all patients. Baseline CT of neck, thorax, 
abdomen, and pelvis were performed in all patients 
before chemotherapy. Patients were reevaluated by 
means of CT after 3 and 6 courses of chemotherapy. The 
treatment response was classified after completion of 6 
cycles of R-CHOP/CHOP as complete response (CR), 
partial response (PR), no change (NC), or progressive 
disease (PD) according to the RECIST 1.1 criteria based 
on the bi-dimensional diameters of corresponding tumor 
lesions measured by ruler or caliper [44]. Further follow 
up evaluations were carried out according to standard 
protocols every 3 months. The median follow-up estimated 
by the inverse Kaplan-Meier method [45] was 32.2 months 
(range: 11.5 – 73.2 months; median: 28.6 months). The 
patient management was not influenced by the results of 
FLT-PET studies. 
Statistical Analysis
Statistical analyses were performed using PASW 
Statistics software (version 20.0; SPSS, Inc. Chicago, 
IL) and the statistical software R [46]. Quantitative 
values were expressed as mean ± standard deviation or 
median and range as appropriate. Comparisons of related 
metric measurements were performed using Wilcoxon-
signed rank test and the Mann-Whitney-U test was used 
to compare quantitative data between two independent 
samples. To assess prognostic impact of continuous 
variables with regard to survival, Martingale-residual 
analysis was performed [47]. Smoothing spline equations 
have been fitted to the residual plots to depict shape of 
functional relationship between the continuous prognostic 
variable and the risk of death.
Fisher’s exact test was used for comparison of 
frequencies and Spearman correlation coefficients 
were calculated to quantify bivariate correlations of 
measurement data. Exact two-sided 95 percent confidence 
intervals (CI) were reported for estimates of sensitivity 
and specificity. In order to assess the discriminative ability 
of FLT-SUV decreases for the dichotomous outcome 
tumor response (complete remission (CR) versus partial 
response (PR) or progressive disease (PD)), receiver 
operating characteristics (ROC) curves were fitted and the 
area under the curve (AUC) along with 95% confidence 
intervals reported. All statistical tests were conducted 
two-sided and a p-value less than 0.05 was considered to 
indicate statistical significance. No correction of p-values 
was considered in the course of multiple testing; however, 
results of all performed tests were thoroughly reported, 
allowing for an informal adjustment for multiplicity while 
reviewing the data [48].
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